Week 3 Wegovy update: separating real results from hype

What did @asideofseraya actually say?

She described three weeks on Wegovy with two dominant side effects: severe diarrhea lasting about two days and persistent fatigue that has her sleeping up to 12 hours daily. She also flagged what she called "stink breath" from going long periods without eating, and reported a net loss of three pounds after regaining six from a vacation.

She was transparent that nausea had mostly resolved by week three, that she keeps xylitol-free gum and a tongue scraper on hand for the breath issue, and that her doctor will decide whether to uptitrate her dose at her next follow-up. She also connected longer fasting periods, driven by appetite suppression, to the unusual breath she noticed.

Credit where it's due: she encouraged viewers to consult their doctors and was upfront about a weight regain episode rather than presenting a tidy success story. That kind of honesty is genuinely rare in GLP-1 content.

Does the science back this up?

Largely, yes. The gastrointestinal side effect profile she described is well-documented in clinical trial data, and her timeline of symptom onset and partial resolution around weeks two to four is consistent with what researchers observed in the STEP trials.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) reported nausea in about 44% of semaglutide participants and diarrhea in roughly 30%, with most GI events concentrated in the early dose-escalation phase. Symptoms typically peaked in the first four to eight weeks. Her experience of diarrhea resolving within two days while fatigue lingered is plausible and not unusual.

On the breath issue: she's describing what is likely hunger ketosis breath, a byproduct of fat metabolism when caloric intake drops sharply. When glycogen stores deplete, the body shifts toward ketone production, and acetone exhaled through the lungs produces a distinctive odor. This is not exclusive to GLP-1 medications but becomes more frequent when appetite suppression dramatically cuts food intake. She connected cause and effect correctly, even without knowing the clinical term.

What did they get wrong (or right)?

She got the side effect framing mostly right, but the fatigue claim deserves a closer look. She treats fatigue as a straightforward GLP-1 side effect, and while it does appear in postmarket reports, it was not among the most prominently reported adverse events in the STEP trials. Davies et al. (2021, Lancet) noted fatigue in a subset of participants but at lower rates than nausea or diarrhea.

It's worth considering alternative explanations. Eating significantly less means consuming fewer calories and possibly fewer micronutrients. Iron, B12, and folate deficiencies can all cause fatigue and are plausible in someone dramatically reducing food intake without structured dietary guidance. She doesn't mention what she's eating, so this is a genuine knowledge gap in her update.

Her three-pound net loss figure is honest but context-free for viewers. Three pounds over three weeks after regaining six sounds modest, but her trajectory, what her starting weight was, her dose, and her activity level all matter. She's not wrong, but the number alone tells viewers very little.

What should you actually know?

If you're starting Wegovy and experience GI side effects like hers, the evidence says most of them do taper off as your body adjusts. The STEP trial data showed symptom rates declined significantly after the titration period ended. Pushing through the early weeks, with medical oversight, is generally the protocol.

The breath she describes is real and under-discussed in GLP-1 content. Ketosis breath is benign but can signal that caloric restriction is significant enough to shift your metabolism. That's not inherently dangerous, but it is a signal worth telling your doctor about, especially if it's persistent.

Fatigue that has you sleeping 12 hours a day warrants a blood panel, not just patience. Ask your provider to check ferritin, B12, and thyroid function if this continues. Don't assume it's just the medication.

Her plan to follow up with her doctor before any dose increase is exactly right. Dose uptitration without clinical oversight is where many people run into avoidable problems with intensified side effects.